Attached files

file filename
EX-10.28 - EX-10.28 - Dare Bioscience, Inc.ceru-ex1028_20141231821.htm
EXCEL - IDEA: XBRL DOCUMENT - Dare Bioscience, Inc.Financial_Report.xls
EX-23.1 - EX-23.1 - Dare Bioscience, Inc.ceru-ex231_20141231988.htm
EX-32.2 - EX-32.2 - Dare Bioscience, Inc.ceru-ex322_20141231827.htm
EX-31.2 - EX-31.2 - Dare Bioscience, Inc.ceru-ex312_20141231825.htm
EX-31.1 - EX-31.1 - Dare Bioscience, Inc.ceru-ex311_20141231824.htm
10-K - 10-K - Dare Bioscience, Inc.ceru-10k_20141231.htm
EX-21.1 - EX-21.1 - Dare Bioscience, Inc.ceru-ex211_20141231823.htm
EX-10.31 - EX-10.31 - Dare Bioscience, Inc.ceru-ex1031_201412311454.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Cerulean Pharma Inc. (the “Company”) for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Christopher D.T. Guiffre, Chief Operating Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 19, 2015

 

/s/ Christopher D. T. Guiffre

Christopher D.T. Guiffre

Chief Operating Officer

(principal executive officer)